TY - JOUR
T1 - Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer
T2 - Long-Term Results of a Prospective Phase II Study
AU - Keizman, Daniel
AU - Frenkel, Moshe
AU - Peer, Avivit
AU - Rosenbaum, Eli
AU - Sarid, David
AU - Leibovitch, Ilan
AU - Mano, Roy
AU - Yossepowitch, Ofer
AU - Wolf, Ido
AU - Geva, Ravit
AU - Margel, David
AU - Rouvinov, Keren
AU - Stern, Anat
AU - Dresler, Hadas
AU - Kushnir, Igal
AU - Eliaz, Isaac
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/8
Y1 - 2023/8
N2 - The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol®-Modified citrus pectin (P-MCP) is a food supplement categorized as GRAS (Generally Recognized As Safe) by the FDA. It is a competitive inhibitor of the galectin-3 protein, which is involved in cancer pathogenesis. In an early report of the present phase 2 study, P-MCP treatment for 6 months led to prostate-specific antigen doubling time (PSADT) improvement in 75% of patients with BRPC-M0. Herein, we report the second long-term treatment phase of an additional 12 months of P-MCP therapy (4.8 g × 3/day orally) in patients without disease progression after the initial 6 months of therapy. Of the 46 patients that entered the second treatment phase, 7 patients withdrew consent and decided to continue therapy out of pocket, and 39 initiated the second treatment phase. After a total of 18 months of P-MCP treatment, 85% (n = 33) had a durable long-term response, with 62% (n = 24) showing decreased/stable PSA, 90% (n = 35) PSADT improvement, and all with negative scans. No patient had grade 3/4 toxicity. In conclusion, P-MCP may have long-term durable efficacy and is safe in BRPC-M0.
AB - The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol®-Modified citrus pectin (P-MCP) is a food supplement categorized as GRAS (Generally Recognized As Safe) by the FDA. It is a competitive inhibitor of the galectin-3 protein, which is involved in cancer pathogenesis. In an early report of the present phase 2 study, P-MCP treatment for 6 months led to prostate-specific antigen doubling time (PSADT) improvement in 75% of patients with BRPC-M0. Herein, we report the second long-term treatment phase of an additional 12 months of P-MCP therapy (4.8 g × 3/day orally) in patients without disease progression after the initial 6 months of therapy. Of the 46 patients that entered the second treatment phase, 7 patients withdrew consent and decided to continue therapy out of pocket, and 39 initiated the second treatment phase. After a total of 18 months of P-MCP treatment, 85% (n = 33) had a durable long-term response, with 62% (n = 24) showing decreased/stable PSA, 90% (n = 35) PSADT improvement, and all with negative scans. No patient had grade 3/4 toxicity. In conclusion, P-MCP may have long-term durable efficacy and is safe in BRPC-M0.
KW - modified citrus pectin
KW - non-metastatic biochemically relapsed prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85168719704&partnerID=8YFLogxK
U2 - 10.3390/nu15163533
DO - 10.3390/nu15163533
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37630724
AN - SCOPUS:85168719704
SN - 2072-6643
VL - 15
JO - Nutrients
JF - Nutrients
IS - 16
M1 - 3533
ER -
